1. Protein Tyrosine Kinase/RTK Membrane Transporter/Ion Channel PI3K/Akt/mTOR MAPK/ERK Pathway Stem Cell/Wnt JAK/STAT Signaling
  2. Anaplastic lymphoma kinase (ALK) ROS Kinase BCRP Akt ERK STAT
  3. Iruplinalkib

Iruplinalkib  (Synonyms: WX-0593)

目录号: HY-145574 纯度: 99.29%
COA 产品使用指南 技术支持

Iruplinalkib (WX-0593) 是一种口服有效的和选择性的 ALK/ROS1 抑制剂。Iruplinalkib 能有效抑制 ALK 和突变型 ALKEGFR 的酪氨酸自磷酸化,IC50 在 5.38 到 16.74 nM之间。Iruplinalkib 也是转运蛋白 MATE1MATE2KP-gp BCRP 的强抑制剂。Iruplinalkib 可用于非小细胞肺癌的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Iruplinalkib Chemical Structure

Iruplinalkib Chemical Structure

CAS No. : 1854943-32-0

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
1 mg ¥681
In-stock
5 mg ¥1500
In-stock
10 mg ¥2500
In-stock
25 mg ¥5500
In-stock
50 mg 现货 询价
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Customer Review

查看 Akt 亚型特异性产品:

查看 ERK 亚型特异性产品:

查看 STAT 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Iruplinalkib (WX-0593) is an orally active and selective ALK/ROS1 inhibitor. Iruplinalkib can effectively inhibit tyrosine autophosphorylation of ALK and mutant ALK, EGFR, with the IC50 between 5.38 and 16.74 nM. Iruplinalkib is also a suppressive agent of the transporter MATE1, MATE2K, P-gp and BCRP. Iruplinalkib can be used in the study of non-small cell lung cancer[1][2].

IC50 & Target

ALK and ROS1[1]

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
BaF3 IC50
1 nM
Compound: 16a; WX-0593
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK L1152P mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK L1152P mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
11 nM
Compound: 16a; WX-0593
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK I1171T mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK I1171T mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
12 nM
Compound: 16a; WX-0593
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK T1151Tins mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK T1151Tins mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
12 nM
Compound: 16a; WX-0593
Antiproliferative activity against mouse BaF3 cells harbouring SLC34A2-ROS1-L2026M mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against mouse BaF3 cells harbouring SLC34A2-ROS1-L2026M mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
13 nM
Compound: 16a; WX-0593
Antiproliferative activity against mouse BaF3 cells harbouring ALK wild type assessed as reduction in cell viability by Celltitre-Glo luminescent assay
Antiproliferative activity against mouse BaF3 cells harbouring ALK wild type assessed as reduction in cell viability by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
15 nM
Compound: 16a; WX-0593
Antiproliferative activity against mouse BaF3 cells harbouring CD74-ROS1-S1986Y mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against mouse BaF3 cells harbouring CD74-ROS1-S1986Y mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
17 nM
Compound: 16a; WX-0593
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK I1171N mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK I1171N mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
21 nM
Compound: 16a; WX-0593
Antiproliferative activity against mouse BaF3 cells harbouring ALK C1156Y mutant assessed as reduction in cell viability by Celltitre-Glo luminescent assay
Antiproliferative activity against mouse BaF3 cells harbouring ALK C1156Y mutant assessed as reduction in cell viability by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
22 nM
Compound: 16a; WX-0593
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK F1174V mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK F1174V mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
22 nM
Compound: 16a; WX-0593
Antiproliferative activity against mouse BaF3 cells harbouring CD74-ROS1-S1986F mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against mouse BaF3 cells harbouring CD74-ROS1-S1986F mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
24 nM
Compound: 16a; WX-0593
Antiproliferative activity against mouse BaF3 cells harbouring ALK L1196M mutant assessed as reduction in cell viability by Celltitre-Glo luminescent assay
Antiproliferative activity against mouse BaF3 cells harbouring ALK L1196M mutant assessed as reduction in cell viability by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
32 nM
Compound: 16a; WX-0593
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK I1171S mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK I1171S mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
33 nM
Compound: 16a; WX-0593
Antiproliferative activity against mouse BaF3 cells harbouring CD74-ROS1-D2033N mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against mouse BaF3 cells harbouring CD74-ROS1-D2033N mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
36 nM
Compound: 16a; WX-0593
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK F1174C mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK F1174C mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
4 nM
Compound: 16a; WX-0593
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK L1152R mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK L1152R mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
BaF3 IC50
8 nM
Compound: 16a; WX-0593
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK V1180L mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
Antiproliferative activity against crizotinib resistant mouse BaF3 cells expressing EML4 fused ALK V1180L mutant assessed as reduction in cell viability incubated for 72 hrs by Celltitre-Glo luminescent assay
[PMID: 35421578]
KARPAS-299 IC50
14.5 nM
Compound: 16a; WX-0593
Antiproliferative activity against human KARPAS-299 cells harbouring wild type ALK assessed as reduction in cell viability by Celltitre-Glo luminescent assay
Antiproliferative activity against human KARPAS-299 cells harbouring wild type ALK assessed as reduction in cell viability by Celltitre-Glo luminescent assay
[PMID: 35421578]
体外研究
(In Vitro)

Iruplinalkib (1.23-100 nM;2 小时) 通过抑制 ALK、RAS/MAPK/ERK、PI3K/AKT 的磷酸化抑制 NCI-H3122 细胞的生长[1]
Iruplinalkib (10-1000 nM;2 小时) 在 NIH-3T3 (CD74-ROS1) 和 Ba/F3 (SLC34A2-ROS1) 细胞中抑制 ROS1 及相关通路关键蛋白的磷酸化[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: NCI-H3122 cells
Concentration: 1.23, 3.7, 11.1, 33.3 and 100 nM
Incubation Time: 2 h
Result: Reduced the phosphorylation levels of ALK, AKT and ERK.

Western Blot Analysis[1]

Cell Line: NIH-3T3 (CD74-ROS1) and Ba/F3 (SLC34A2-ROS1) cells
Concentration: 10, 100 and 1000 nM
Incubation Time: 2 h
Result: Reduced the phosphorylation levels of ROS1 and AKT in NIH-3T3 cells.
Reduced the phosphorylation levels of ROS1, Erk and SHP-1 in Ba/F3 cells.
体内研究
(In Vivo)

Iruplinalkib (2.5-10 mg/kg;口服;3 周) 在非小细胞肺癌小鼠模型中具有抗肿瘤的作用[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: EML4-ALK transfected NCI-H3122 treated female BALB/c nude mice (4-6 weeks old)[1]
Dosage: 2.5, 5 and 10 mg/kg
Administration: Oral administration (p.o.); 3 weeks
Result: Inhibited tumor growth.
Had inhibitory effects on the phosphorylation of ALK, AKT and ERK.
Decreased the levels of phosphorylation of STAT3 and STAT5.
Had no effect on the body weight.
Clinical Trial
分子量

569.08

Formula

C29H38ClN6O2P

CAS 号
性状

固体

颜色

Off-white to light yellow

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 10 mg/mL (17.57 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7572 mL 8.7861 mL 17.5722 mL
5 mM 0.3514 mL 1.7572 mL 3.5144 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
纯度 & 产品资料
参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.7572 mL 8.7861 mL 17.5722 mL 43.9306 mL
5 mM 0.3514 mL 1.7572 mL 3.5144 mL 8.7861 mL
10 mM 0.1757 mL 0.8786 mL 1.7572 mL 4.3931 mL
15 mM 0.1171 mL 0.5857 mL 1.1715 mL 2.9287 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Iruplinalkib
目录号:
HY-145574
需求量: